12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Company News  |  Deals

Visterra, Pfizer deal

Visterra made its public debut by announcing its first pharma deal and presenting preclinical data for its lead compound. Visterra partnered with Pfizer to discover antibodies using the biotech's atomic interaction network analysis technology for undisclosed indications. Visterra will receive an upfront payment and research funding, and will...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >